← Leaderboards
Peter A Merkel
Boston University Medical Campus
$5,234,800
Attributed
$5,234,800
Total exposure
10
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$8,984,800 · 11
By mechanism
U54$6,250,000 · 2
M01$2,125,501 · 8
K24$609,299 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Timothy E McAlindon$15,710,823
- David Tobin Felson$45,961,276
- Raul I Garcia$11,083,684
- Manish Bais$3,000,764
- Douglas V Faller$14,088,389
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchCystic FibrosisLongitudinal Human StudyGenotypePathologic ProcessEpidemiologyOsteoporosisComorbidityBiomarkerDrug Screening /EvaluationHuman Therapy EvaluationPatient Oriented ResearchChloride ChannelsChild (0-11)ArthritisJoint DisorderGenetic MarkersMedical ComplicationBone DensityQuality Of LifeRheumatoid ArthritisOrphan Disease /DrugMedical Outreach /Case Finding
Grant awards (35)
VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASE$1,250,000
U54 · FY2005 · RR
Vasculitis Clinical Research Network (VCRN)$1,250,000
U54 · FY2005 · RR
Studies in Scleroderma and Cystic Fibrosis Osteoporosis$127,550
K24 · FY2005 · AR
STUDY OF ENBREL IN THE TREATMENT OF WEGENER'S GRANULOMATOSIS$12,523
M01 · FY2005 · RR
DEVELOPMENT AND VALIDATION OF OUTCOME MEASURES FOR SYSTEMIC SCLEROSIS$7,367
M01 · FY2005 · RR
GENETIC POLYMORPHISMS IN WEGENER'S GRANULOMATOSIS$2,578
M01 · FY2005 · RR
VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASE$1,250,000
U54 · FY2004 · RR
Vasculitis Clinical Research Network (VCRN)$1,250,000
U54 · FY2004 · RR
Studies in Scleroderma and Cystic Fibrosis Osteoporosis$124,620
K24 · FY2004 · AR
Study of Enbrel in Treatment of Wegener's Granulomatosis$23,147
M01 · FY2004 · RR
Outcome Measures for Systemic Sclerosis$6,871
M01 · FY2004 · RR
Genetic Polymorphisms in Wegener's Granulomatosis$3,255
M01 · FY2004 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN PTS WITH CYSTIC FIBROSIS$1,107
M01 · FY2004 · RR
Vasculitis Clinical Research Network (VCRN)$1,250,000
U54 · FY2003 · RR
Studies in Scleroderma and Cystic Fibrosis Osteoporosis$121,776
K24 · FY2003 · AR
PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY$200,768
M01 · FY2002 · RR
PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY$200,768
M01 · FY2002 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN CYSTIC FIBROSIS$200,768
M01 · FY2002 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN CYSTIC FIBROSIS$200,768
M01 · FY2002 · RR
Studies in Scleroderma and Cystic Fibrosis Osteoporosis$119,016
K24 · FY2002 · AR
PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY$200,768
M01 · FY2001 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN CYSTIC FIBROSIS$200,768
M01 · FY2001 · RR
Studies in Scleroderma and Cystic Fibrosis Osteoporosis$116,337
K24 · FY2001 · AR
PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY$0
M01 · FY2001 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN CYSTIC FIBROSIS$0
M01 · FY2001 · RR
STUDY ADMINISTERING MYCOPHENOLATE MOFETIL FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
EFFICACY/SAFETY OF MYCOPHENOLATE MOFETIL IMMUNOTHERAPY IN RHEUMATOID ARTHRITIS$415,629
M01 · FY2000 · RR
ADMINISTERING (MMF RS 61443) PO (1G BID) IN PTS W/ ACTIVE RHEUMATOID ARTHRITIS$415,629
M01 · FY2000 · RR
STUDY ADMINISTERING MYCOPHENOLATE MOFETIL FOR ACTIVE RHEUMATOID ARTHRITIS$30,487
M01 · FY2000 · RR
PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY$575
M01 · FY2000 · RR
ADMINISTERING (MMF RS 61443) PO (1G BID) IN PTS W/ ACTIVE RHEUMATOID ARTHRITIS$575
M01 · FY2000 · RR
EFFICACY/SAFETY OF MYCOPHENOLATE MOFETIL IMMUNOTHERAPY IN RHEUMATOID ARTHRITIS$575
M01 · FY2000 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN CYSTIC FIBROSIS$575
M01 · FY2000 · RR
CLINICAL AND BIOCHEMICAL MARKERS OF OSTEOPOROSIS IN CYSTIC FIBROSIS$0
M01 · FY2000 · RR
PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY$0
M01 · FY2000 · RR